Emilee Cope, in Austin, AR - Social Worker

Emilee Cope, is a Social Worker - Clinical based in Austin, Arkansas. Emilee Cope is licensed to practice in Arkansas (license number 8431-C) and her current practice location is 712 Mango Loop, Austin, Arkansas. She can be reached at her office (for appointments etc.) via phone at (501) 259-8266.

NPI number for Emilee Cope is 1205519360 and her current mailing address is 712 Mango Loop, Austin, Arkansas. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1205519360.

Contact Information

	Emilee Cope,
	712 Mango Loop, Austin, AR 72007-8400
	(501) 259-8266
	Not Available

Healthcare Provider's Profile

Full Name	Emilee Cope
Gender	Female
Speciality	Social Worker - Clinical
Location	712 Mango Loop, Austin, Arkansas
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1205519360
Provider Enumeration Date: 08/07/2023
Last Update Date: 08/07/2023

Medical Identifiers

Medical identifiers for Emilee Cope such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1205519360	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
1041C0700X	Social Worker - Clinical	8431-C (Arkansas)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Emilee Cope is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Emilee Cope, 712 Mango Loop, Austin, AR 72007-8400 Ph: () -	Emilee Cope, 712 Mango Loop, Austin, AR 72007-8400 Ph: (501) 259-8266

News Archive

New image analysis technique helps better identify and distinguish between two cancer cell types

Brown University researchers have developed a new image analysis technique to distinguish two key cancer cell types associated with tumor progression.

Onyx reports total operating revenue of $237.0M for fourth quarter 2011

Onyx Pharmaceuticals, Inc. today reported its financial results for the full year and fourth quarter 2011. Onyx reported non-GAAP net income of $42.0 million, or $0.66 per diluted share, for the full year 2011 compared to non-GAAP net income of $39.2 million, or $0.63 per diluted share, for the same period in 2010.

Scientists design new computational strategy to enable more personalized cancer treatment

Mathematicians and cancer scientists have found a way to simplify complex biomolecular data about tumors, in principle making it easier to prescribe the appropriate treatment for a specific patient.

NEI awards Case Western Reserve $10M for study of retinal diseases

The Departments of Pharmacology and Ophthalmology and Visual Sciences at Case Western Reserve University School of Medicine have been awarded a $10.1 million grant from the National Eye Institute (NEI) to research and develop new treatments for diseases of the retina, a leading cause of blindness.

Lund researchers develop new mouse model to better understand type 2 diabetes in humans

Researchers at Lund University in Sweden have developed a new mouse model that answers the question of what actually happens in the body when type 2 diabetes develops and how the body responds to drug treatment.

Emilee Cope, - Clinical Social Worker in Austin, AR